newsfilter
← Latest News
PR Newswire·

MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT

NEW YORK, July 28, 2021 /PRNewswire/ -- MindMed (NASDAQ:MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the start of a Phase 1 clinical trial to assess the safety, pharmacokinetics